Weakened cross-border healthcare directive will disappoint manufacturers of orphan drugs
This article was originally published in Scrip
The cross-border healthcare directive will not, as previously hoped, give patients with rare diseases the right to access to orphan drugs in other countries when the treatment is not reimbursed in the patient's own member state. Companies producing orphan drugs will not get the financial and legal security they had hoped for.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.